NPH16

C57BL/6 mice bearing HEPA1-6 hepatoma tumors^[1]

50 mg/kg, 100 mg/kg

Oral gavage (p.o.), for 7 days

Caused no significant weight loss or adverse reactions in the mice.
Demonstrated significant dose-dependent antitumor activity throughout the treatment period.
Reduced tumor weight and volume by 92.1% and 91.2%, respectively at a dose of 100 mg/kg.
Significantly decreased the tumor weight and volume, amounting to 77.5% and 74.8%, respectively at a dose of 50 mg/kg.
Maintained the cellular boundaries within the organ tissues distinct and no obvious cell necrosis observed.
Significantly reduced PD-L1 expression by approximately 40%.
Markedly elevated IFN-γ levels in tumor tissues (5.4-fold increase vs control) .
Increased the percentage of CD3⁺CD8⁺ cells (activated cytotoxic T cells) to 3.9% at a dose of 100 mg/kg.
Significantly reduced splenic Treg populations (0.7% vs 2.6% in vehicle controls), while producing a modest decrease in intratumoral Tregs at a dose of 100 mg/kg.
Substantially downregulated TIM3 protein expression relative to control groups(100 mg/kg) .